Cyclacel Pharmaceuticals Financials
| CYCCP Preferred Stock | USD 5.80 0.04 0.69% |
Cyclacel |
Understanding current and past Cyclacel Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cyclacel Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Cyclacel Pharmaceuticals' assets may result in an increase in income on the income statement.
Cyclacel Pharmaceuticals Preferred Stock Summary
Cyclacel Pharmaceuticals competes with Checkpoint Therapeutics, Mustang Bio, Reviva Pharmaceuticals, Kodiak Sciences, and Fortress Biotech. Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Specialization | Healthcare, Biotechnology |
| Instrument | USA Preferred Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US23254L2079 |
| CUSIP | 23254L207 |
| Location | New Jersey; U.S.A |
| Business Address | 200 Connell Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cyclacel.com |
| Phone | 908 517 7330 |
| Currency | USD - US Dollar |
Cyclacel Pharmaceuticals Key Financial Ratios
Cyclacel Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Cyclacel Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Cyclacel Pharmaceuticals over time and compare it to other companies across industries.Cyclacel Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclacel Pharmaceuticals competition to find correlations between indicators driving Cyclacel Pharmaceuticals's intrinsic value. More Info.Cyclacel Pharmaceuticals is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Cyclacel Pharmaceuticals Systematic Risk
Cyclacel Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cyclacel Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Cyclacel Pharmaceuticals correlated with the market. If Beta is less than 0 Cyclacel Pharmaceuticals generally moves in the opposite direction as compared to the market. If Cyclacel Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cyclacel Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cyclacel Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Cyclacel Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Cyclacel Pharmaceuticals December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cyclacel Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cyclacel Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Cyclacel Preferred Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cyclacel Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 24.03 | |||
| Value At Risk | (9.08) | |||
| Potential Upside | 5.8 |
Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.